Mammaprint is a test that puports to determine agressiveness of breast cancer. It is widely accepted in Europe and less so in the USA.More recently, Mammaprint had been marketed as a Symphony Panel that also includes the microarray-based test. TargetPrint is another iteration that puports to provides reliable, quantitative assessment of mRNA expression levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) and BluePrint.
Besides that these two tests still need to be fully validated, there is no literature support for the three together being more accurate or productive of more benefit than either one. Therefore, it may be interesting tofarther test combinations of these assays. The same holds true of BluePrint, an 80-gene expression signature for the classification of breast cancer into Basal-type, Luminal-type and ERBB2-type.
For Professional version see here